ArticleBiomedical reports2016
Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point.
Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Clinical Features and Pathology of PLA2R and THSD7A-Associated Membranous Nephropathy: A Single-Center Study from China.ImmunoTargets and therapy · 2024Trial
- Histopathological predictors of renal outcomes in idiopathic membranous nephropathy with a focus on global sclerotic glomeruli ratio.Scientific reports · 2026Article
- A membranous nephropathy variant mimicking minimal change disease.The journal of pathology. Clinical research · 2026Article
- Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy.American journal of translational research · 2026Article
- Renal tubulointerstitial lesions: a prognostic marker in idiopathic membranous nephropathy.Renal failure · 2025Article
- Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing pathological features and kidney prognosis.Scientific reports · 2025Article
- Spontaneous remission in primary membranous nephropathy: mechanisms, predictive factors, and implications for personalized management.Frontiers in immunology · 2025Review
- Clinical significance of exostosin 1 in confirmed and suspected lupus membranous nephropathy.Lupus science & medicine · 2023Article
- Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.Renal failure · 2023Article
- Clinical characteristics and prognosis of patients with idiopathic membranous nephropathy with kidney tubulointerstitial damage.Renal failure · 2023Article
- Prognostic prediction of idiopathic membranous nephropathy using interpretable machine learning.Renal failure · 2023Article
- Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- Glomerulosclerosis predicts poor renal outcome in patients with idiopathic membranous nephropathy.International urology and nephrology · 2021Article
- Article
- Clinicopathological features and prognosis in patients with idiopathic membranous nephropathy with hypertension.Experimental and therapeutic medicine · 2020Article
- Clinical implications of pathological features of primary membranous nephropathy.BMC nephrology · 2018Article
- Factors affecting the long-term outcomes of idiopathic membranous nephropathy.BMC nephrology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic membranous nephropathy (IMN) is one of the most common causes of nephrotic syndrome (NS) in adults. The latest study of the chronic kidney disease-prognosis consortium showed that a 30% decrease in the estimated glomerular filtration rate (eGFR) within 2 years could cover more patients and showed a better correlation with end-stage renal disease (ESRD), as compared with serum creatinine (SCr). The aim of the present study was to analyze prognostic factors of ESRD using a 30% decrease in eGFR within 2 years as the end-point. The medical records of patients who were diagnosed as having IMN by clinical pathology between February 2011 and August 2012 and had been followed up for ≥24 months were analyzed retrospectively. A 30% decrease in eGFR or the occurrence of ESRD were the end-points. Factors affecting the prognosis were analyzed by the χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.